Drug Profile
Research programme: hedgehog inhibitors - Abraxis BioScience
Alternative Names: ABI-2088; HH inhibitors - AbraxisLatest Information Update: 23 Jan 2014
Price :
$50
*
At a glance
- Originator Abraxis BioScience
- Developer Celgene Corporation
- Class
- Mechanism of Action Hedgehog protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Nov 2010 Preclinical trials in Cancer in USA (Parenteral)
- 19 Nov 2010 Preclinical trials in Cancer in USA (PO)